Lutetium-177 PSMA Therapy for Prostate Cancer in India — Who Qualifies, How It Works, and Where to Access It in 2026
For most of the past two decades, Indian men diagnosed with advanced prostate cancer had a fairly narrow set of treatment options — hormone therapy, chemotherapy if the cancer progressed, and more recently oral targeted medicines like Enzalutamide (Glenza) and Abiraterone (Abirapro). These are genuinely effective medicines, but they work for a limited time in […]
Enhertu and the ADC Revolution — Why Antibody-Drug Conjugates Are the Most Important Development in Cancer Treatment in 2026
In December 2019 the FDA approved a new cancer medicine that most oncologists had never heard of. By 2024 it had become the best-selling antibody-drug conjugate in the world — generating USD 3.75 billion in annual sales. By early 2026 it had received Priority Review for yet another new indication and was being described by […]
Ozempic vs Mounjaro vs Wegovy in India 2026 — Which GLP-1 Should Your Patient Choose?
India’s diabetes and obesity treatment landscape changed dramatically in March 2026. Novo Nordisk’s core Indian patent for semaglutide expired on March 20, 2026 — within hours, a wave of Indian pharmaceutical companies launched their own versions at dramatically lower prices. Branded Ozempic costs ₹8,800–₹11,175 per month in India, while the cheapest generic is now available […]
How A.K. Pharma Ensures Genuine Medicine Supply Across India
When hospitals, clinics, and pharmacies look for a medicine supplier, the most important factor is trust. Counterfeit or substandard medicines are a serious concern in India — and choosing the wrong supplier can put patients at risk. At A.K. Pharma, we understand this responsibility. As a licensed medicine wholesaler in Delhi, we have built our […]